Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q2 FY27 Net Profit up 2.21% YoY to 2,042.61 Lakhs
RESULTS
◆ Monitor Closely
LOW RISK
📅 Filed on BSE: 29 Oct 2026, 12:27 PM IST · BSE ID: 9acc7c1b-3f4c-4aed-8b26-0d83ef019be7
View Original BSE Filing (PDF)
💡
In Simple Terms
Lincoln Pharmaceuticals announced its latest financial results, showing an increase in profit for the quarter and half year.
🤖 AI Summary
- Net Profit for Q2 FY27 increased to 2,042.61 Lakhs, up from 1,998.40 Lakhs in Q2 FY26.
- Revenue from Operations for the quarter ended September 30, 2026, was 19,134.51 Lakhs.
- Half-year Net Profit (H1 FY27) stood at 5,666.06 Lakhs, against 4,765.92 Lakhs in H1 FY26.
- Half-year Revenue from Operations (H1 FY27) reached 36,862.72 Lakhs, compared to 31,743.06 Lakhs in H1 FY26.
- The Board of Directors considered and approved the unaudited standalone financial results on October 29, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
19,134.51 Lakhs
Net Profit (Q2 FY27)
2,042.61 Lakhs
2.21%
Revenue from Operations (H1 FY27)
36,862.72 Lakhs
16.10%
Net Profit (H1 FY27)
5,666.06 Lakhs
18.89%
Basic EPS (Q2 FY27)
10.20
2.20%
Basic EPS (H1 FY27)
28.29
18.92%
🏢 How This Affects the Company
The company's core pharmaceutical business generated 19,134.51 Lakhs in Q2 FY27 revenue, indicating sustained operational activity.
Net Profit for Q2 FY27 was 2,042.61 Lakhs, an increase from the prior year's corresponding period, contributing to overall financial performance.
Not directly indicated by the financial results in this filing.
Not directly indicated by the financial results in this filing.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these results reflect the company's financial performance for the quarter and half year ended September 30, 2026.
🔍
Management Signal
The approval of unaudited financial results by the Board of Directors signals adherence to regulatory disclosure requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — check for revenue and profit trends.
Updates on new product launches or market expansions.
Any further board meeting outcomes regarding strategic initiatives.
LOW RISK
The filing reports routine quarterly financial results with consistent YoY growth.
💡 Investor Takeaway
Lincoln Pharmaceuticals Ltd reported Q2 FY27 Net Profit of 2,042.61 Lakhs, up 2.21% from 1,998.40 Lakhs in Q2 FY26. Half-year Net Profit for H1 FY27 increased 18.89% to 5,666.06 Lakhs compared to H1 FY26.
⚖️ Strengths & Concerns
✅ Positives
- Net Profit for Q2 FY27 increased to 2,042.61 Lakhs, up 2.21% from 1,998.40 Lakhs in Q2 FY26.
- Half-year Net Profit for H1 FY27 grew to 5,666.06 Lakhs, an increase of 18.89% from 4,765.92 Lakhs in H1 FY26.
⚠️ Concerns
- Quarter-on-quarter (QoQ) Net Profit decreased from 3,623.45 Lakhs in Q1 FY27 to 2,042.61 Lakhs in Q2 FY27.
- Total Income for Q2 FY27 was 20,087.91 Lakhs, a slight decrease from 20,154.67 Lakhs in Q1 FY27.
📅 Company Track Record
Lincoln Pharmaceuticals reported a Q2 FY27 Net Profit of 2,042.61 Lakhs, showing a 2.21% year-on-year increase compared to 1,998.40 Lakhs in Q2 FY26. Half-year results also show consistent growth.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Lincoln Pharmaceuticals' Net Profit in Q2 FY27?
Lincoln Pharmaceuticals reported a Net Profit of 2,042.61 Lakhs for the quarter ended September 30, 2026 (Q2 FY27), up from 1,998.40 Lakhs in Q2 FY26.
What was Lincoln Pharmaceuticals' Revenue from Operations for Q2 FY27?
Revenue from Operations for Lincoln Pharmaceuticals was 19,134.51 Lakhs for the quarter ended September 30, 2026.
What was Lincoln Pharmaceuticals' Net Profit for the half year ended September 30, 2026?
For the half year ended September 30, 2026 (H1 FY27), Lincoln Pharmaceuticals reported a Net Profit of 5,666.06 Lakhs, compared to 4,765.92 Lakhs in H1 FY26.
What was Lincoln Pharmaceuticals' Basic Earnings Per Share (EPS) for Q2 FY27?
The Basic Earnings Per Share (EPS) for Lincoln Pharmaceuticals in Q2 FY27 was 10.20, an increase from 9.98 in Q2 FY26.
Questions based on this BSE filing only. For information purposes.